Company Filing History:
7 out of 869 
3 out of 1,743 
2 out of 712 
Years Active: 2006-2024
Title: The Innovative Contributions of Matthew Albert
Introduction
Matthew Albert is a prominent inventor based in Paris, France, known for his significant contributions to the field of immunology. With a total of nine patents to his name, Albert has made remarkable strides in enhancing tumor immunity and immunotherapy.
Latest Patents
One of his latest patents focuses on the inhibition of dipeptidylpeptidase 4 (DPP4), which enhances lymphocyte trafficking, thereby improving both naturally occurring tumor immunity and immunotherapy. The success of anti-tumor immune responses relies on effector T cells infiltrating solid tumors, a process guided by chemokines. Albert's research demonstrates that the in vivo post-translational processing of chemokines by DPP4 limits lymphocyte migration to sites of inflammation and tumors. By inhibiting DPP4 enzymatic activity, tumor rejection is enhanced through the preservation of biologically active CXCL10, which increases lymphocyte trafficking into tumors. Furthermore, DPP4 inhibition has shown to improve adjuvant-based immunotherapy, adoptive T cell transfer, and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors as a strategy to enhance tumor immunotherapy.
Career Highlights
Matthew Albert has worked with prestigious institutions such as the Institut Pasteur and the Institut National de la Santé et de la Recherche Médicale. His work in these organizations has significantly contributed to advancements in medical research and therapeutic strategies.
Collaborations
Albert has collaborated with notable colleagues, including Rosa Barreira Da Silva and Jeremie Decalf, further enriching his research endeavors and expanding the impact of his work.
Conclusion
Matthew Albert's innovative research and patents have made a substantial impact on the field of immunology, particularly in enhancing tumor immunity and immunotherapy. His contributions continue to pave the way for future advancements in cancer treatment.